摘要
目的 探讨齐拉西酮对女性精神分裂疾病患者的疗效及对此类患者生活质量的影响情况.方法 按照数字随机表方式,将精神分裂症患者研究对象80例随机划分为两组,齐拉西酮组患者40例,舒必利组患者40例.齐拉西酮组患者采取给予齐拉西酮药物的方式进行治疗.起始给药量确定为40 mg/d,给药剂量范围在60～ 160mg/d之内,治疗12周确定为1个疗程;同时,舒必利组患者采取给予舒必利药物的方式进行治疗.起始给药量确定为200 mg/d,给药剂量范围在60～1 200 mg/d之内,同样以治疗12周为1个疗程.观测对象为：两组患者治疗之前与接受治疗1疗程后的疗效情况;治疗过程中存在的不良反应;治疗后患者的生活质量.观测指标为：PANSS阳性与阴性症状量表（测定结果反映患者疗效情况）、TESS副反应量表（测定结果反映患者接受治疗中的不良反应情况）、GQOLI生活质量综合评定问卷（测定结果反映患者接受治疗后的生活质量情况）.结果：治疗12周后,两组阳性与阴性症状量表评分均明显下降（均P＜0.01）.齐拉西酮组生活质量综合评定问卷总分及躯体健康、心理健康和社会功能维度评分均显著提高（均P＜0.01）,且均明显优于舒必利组（均P＜0.01）.齐拉西酮组副反应量表评分明显低于舒必利组（P＜0.01）.结论：齐拉西酮与舒必利疗效相当,但齐拉西酮不良反应少,明显改善女性患者生活质量.
Objective To explore the therapeutic effect of ziprasidone on female patients with schizophrenia and their quality of life. Methods According to the random number table method, 80 cases of schizophrenic patients were randomly divided into two groups, ziprasidone group and sulpiride group with 40 cases in each. The two groups were treated by ziprasidone and sulpiride, respectively for a period of 12 weeks, a course of treatment. Ziprasidone group： the initial dose： 40 mg/d; the dose range： 60mg/d ~ 160mg/d. Sulpiride group： the initial dose： 200 mg/d; the dose range： 600 ~ 1200 mg/d. Observation objects： the curative effect before and after 1 course of treatment of the two groups; adverse reactions occurred in the treatment process; the quality of life of the patients after the treatment. Observation indicators： By adopting forms of the Positive and Negative Symptom Scale （PANSS）, the Treatment Emergent Symptom Scale （TESS）, and the General Quality of Life Inventory （GQOLI）, make an evaluation on the two groups in terms of therapeutic effect, adverse reactions in the treatment and quality of life after 12 weeks of treatment. Results After 12 weeks of treatment, the PANSS scores of both groups decreased significantly （avg. P〈0.01） For the ziprasidone group, the total scores of GQOLI and scores of physical health, psychological health as well as social function dimensions increased remarkably （avg. P〈0.1）, and higher than those of the sulpiride group （avg. P〈0.1）. The scores of TESS of the ziprasidone group were observably lower than those of the sulpiride group. Conclusion The therapeutic effect of ziprasidone and sulpiride is comparably similar, but ziprasidone brings less adverse reactions and prominently improves the quality of life of the female patients.
出处
《中外医疗》
2013年第29期39-41,共3页
China & Foreign Medical Treatment
